stockrow
Sunday 8 November 2026
Export OGN’s income statement to Excel — free account
Organon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
13.87
0.08
+0.58%
Follow OGN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
9.96 | 6.37 | 17.14 | 17.13 |
P/S ratio |
0.30 | 0.25 | 0.58 | 0.59 | |
P/FCF ratio |
4.48 | 2.79 | 7.66 | 6.29 | |
P/Operating CF |
13.20 | 6.93 | 33.23 | 9.72 | |
P/B ratio |
2.47 | 1.73 | 3.53 | 3.02 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.60 | 1.46 | 1.79 | 1.75 | |
EV/EBITDA |
6.92 | 6.33 | 7.78 | 7.49 | |
EV/Operating CF |
14.19 | 10.60 | 14.89 | 12.69 | |
EV/FCF |
23.93 | 16.09 | 23.66 | 18.70 | |
Quick Ratio |
0.80 | 1.00 | 1.00 | 1.11 | |
Current Ratio |
1.82 | 1.97 | 1.95 | 2.02 | |
Net Debt/EBITDA |
30.45 | 23.59 | 18.06 | 16.24 | |
Debt/Assets |
67.18% | 65.94% | 64.90% | 63.83% | |
Debt/Equity |
11.49 | 9.49 | 8.50 | 7.17 | |
Asset Turnover |
0.48 | 0.47 | 0.46 | 0.45 | |
Operating CF/Net income |
(0.69) | 1.54 | 0.99 | 2.26 | |
Capex/Depreciation |
(0.13) | (0.46) | (0.85) | (0.61) | |
Interest Coverage |
(0.75) | 2.12 | 2.98 | 3.44 | |
Research and Development Expense of Revenue |
6.04% | 6.37% | 5.78% | 5.27% | |
Selling, General and Administrative Expense of Revenue |
28.73% | 29.04% | 27.86% | 26.75% | |
Intangible Assets out of Total Assets |
0.41 | 0.40 | 0.40 | 0.39 | |
Share Based Compensation of Revenue |
0.46% | 1.30% | 1.60% | 1.33% | |
Graham Net Nets |
(4.17) | (4.59) | (1.99) | (1.90) | |
Graham Number |
6.85 | 8.56 | 8.25 | 9.04 | |
Earnings Yield |
10.04% | 15.69% | 5.83% | 5.84% | |
Free Cash Flow Yield |
22.30% | 35.91% | 13.05% | 15.90% | |
Revenue per Share |
5.81 | 5.61 | 5.93 | 5.99 | |
Operating CF per Share |
0.54 | 0.86 | 0.41 | 1.41 | |
Capex per Share |
(0.17) | (0.14) | (0.29) | (0.17) | |
Free Cash Flow per Share |
0.37 | 0.72 | 0.12 | 1.24 | |
Cash per Share |
2.21 | 4.29 | 4.31 | 5.54 | |
Shareholders Equity per Share |
2.90 | 3.47 | 3.83 | 4.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.90 | 3.47 | 3.83 | 4.54 | |
Free Cash Flow |
96.00 | 188.00 | 31.00 | 326.00 | |
Working Capital |
1,962.00 | 2,432.00 | 2,495.00 | 2,717.00 | |
Capital Expenditures |
(45.00) | (37.00) | (76.00) | (44.00) | |
Net Current Asset Value |
(7,763.00) | (7,161.00) | (7,061.00) | (6,839.00) | |
EV/EBIT |
12.05 | 10.91 | 13.32 | 12.87 | |
Capex to Sales |
0.03 | 0.03 | 0.05 | 0.03 | |
Price to Operating Income |
2.26 | 1.89 | 4.32 | 4.33 | |
| Other line items | |||||
Average Receivables |
1,344.50 | 1,420.50 | 1,488.00 | 1,482.00 | |
Average Payables |
1,052.50 | 994.50 | 1,059.00 | 1,028.00 | |
Average Inventory |
1,363.50 | 1,367.50 | 1,402.50 | 1,421.50 | |
Average Assets |
12,984.00 | 13,076.00 | 13,339.00 | 13,476.50 | |
Average Common Equity |
612.00 | 722.50 | 869.50 | 1,049.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026